Inhibition of mixtures of surfactant lipids and synthetic sequences of surfactant proteins SP-B and SP-C.
The respiratory distress syndrome of premature infants is caused by both surfactant deficiency and surfactant inhibition by capillary-alveolar leakage of serum factors. Dispersions of a standard surfactant lipid mixture, with and without various synthetic peptides, modeled on human surfactant proteins SP-B (residues 1-25, 49-66, 1-78) and SP-C (residues 1-10), were evaluated for inhibition by serum and by plasma constituents using a pulsating bubble surfactometer. Inhibition was derived from the changes in surface properties of these mixtures after addition of human serum or plasma constituents. Modified bovine surfactant (TA) containing native SP-B and SP-C was used as a control. In the absence of serum inhibitors, mixtures with synthetic peptides gave results similar to surfactant TA. However, inhibition was more evident in the dispersions with synthetic peptides when compared with surfactant TA. The peptide/phospholipid mixture with the entire sequence of SP-B and the first 10 residues of SP-C were more resistant to inhibition than mixtures with synthetic peptides containing fewer domains. Addition of calcium reduced the inhibitory effects of serum both in mixtures containing synthetic peptides and in surfactant TA. Therefore, synthetic SP-B and SP-C peptides in surfactant lipids, in cooperation with calcium, permit resistance to inhibition by several plasma constituents that probably inactivate surfactant by a variety of different mechanisms.
Amirkhanian
J D
JD
Department of Pediatrics, King/Drew Medical Center, Los Angeles, CA 90059.
Bruni
R
R
Waring
A J
AJ
Taeusch
H W
HW
D000328:Adult; D000595:Amino Acid Sequence; D001790:Blood Physiological Phenomena; D002118:Calcium / Q000494:pharmacology; D006801:Humans; D008969:Molecular Sequence Data; D010446:Peptide Fragments / Q000037:antagonists & inhibitors / Q000138:chemical synthesis; D010743:Phospholipids / Q000378:metabolism; D011510:Proteolipids / Q000037:antagonists & inhibitors* / Q000138:chemical synthesis; D011663:Pulmonary Surfactants / Q000037:antagonists & inhibitors* / Q000138:chemical synthesis; D013499:Surface Properties
D010446:Peptide Fragments; D010743:Phospholipids; D011510:Proteolipids; D011663:Pulmonary Surfactants; D002118:Calcium